MedPath

DAIICHI SANKYO, INC.

DAIICHI SANKYO, INC. logo
🇯🇵Japan
Ownership
Subsidiary
Established
2010-01-01
Employees
10K
Market Cap
$79B
Website
http://daiichisankyo.us

Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe Hypertension

Phase 3
Completed
Conditions
Hypertension
First Posted Date
2005-09-16
Last Posted Date
2018-12-24
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
1900
Registration Number
NCT00185133

An Examination of the Safety and Blood Pressure Lowering Effect of Increasing Doses of Benicar® and Benicar® HCT in Patients With Hypertension

Phase 4
Completed
Conditions
Hypertension
First Posted Date
2005-09-16
Last Posted Date
2005-09-16
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
110
Registration Number
NCT00185068

The Relative Effects of Olmesartan Medoxomil, Irbesartan and Valsartan on the Activity of the Blood Pressure Control System in Healthy Subjects

Phase 4
Completed
Conditions
Healthy
First Posted Date
2005-09-16
Last Posted Date
2005-09-16
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
20
Registration Number
NCT00185055

Treatment of High Blood Pressure Using Olmesartan With Hydrochlorothiazide Compared to an ACE Inhibitor With a Calcium Channel Blocker

Phase 4
Completed
Conditions
Hypertension
First Posted Date
2005-09-16
Last Posted Date
2012-01-18
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
152
Registration Number
NCT00185120
Locations
🇺🇸

Memorial Research Medical Center, Long Beach, California, United States

🇺🇸

National Research Institute, Los Angeles, California, United States

🇺🇸

Clinical Trials Research, Roseville, California, United States

and more 16 locations

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Coronary Artery Disease

Phase 2
Completed
Conditions
Coronary Heart Disease
First Posted Date
2005-09-16
Last Posted Date
2007-09-11
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
534
Registration Number
NCT00185042

Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol

Phase 4
Completed
Conditions
Hypercholesterolemia
First Posted Date
2005-09-16
Last Posted Date
2007-09-11
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
45
Registration Number
NCT00185107
Locations
🇺🇸

Scripps Clinic, San Diego, California, United States

🇺🇸

Renstar Medical Research, Ocala, Florida, United States

🇺🇸

Radiant Research, Edina, Minnesota, United States

and more 3 locations

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

Phase 4
Completed
Conditions
Metabolic Syndrome
Hypertension
Insulin Resistance
First Posted Date
2005-09-16
Last Posted Date
2005-12-23
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
60
Registration Number
NCT00185094

Assessment of Efficacy and Safety of Olmesartan Medoxomil in Children and Adolescent Patients With High Blood Pressure

Phase 2
Completed
Conditions
Hypertension
Interventions
First Posted Date
2005-09-09
Last Posted Date
2016-06-30
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
362
Registration Number
NCT00151775

WelChol® and Insulin in Treating Patients With Type 2 Diabetes

Phase 3
Completed
Conditions
Type 2 Diabetes
First Posted Date
2005-09-09
Last Posted Date
2012-01-18
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
260
Registration Number
NCT00151749

Efficacy and Safety of the ACAT Inhibitor CS-505 (Pactimibe) for Reducing the Progression of Carotid Artery Disease. This Study is Also Known as CAPTIVATE.

Phase 2
Terminated
Conditions
Atherosclerosis
Heterozygous Familial Hypercholesterolemia
First Posted Date
2005-09-09
Last Posted Date
2012-01-18
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
796
Registration Number
NCT00151788
© Copyright 2025. All Rights Reserved by MedPath